{"slug":"lysa","tag":"lysa","variants":["lysa"],"description":"No description yet","count":3,"kinds":{"person":3},"related":[{"slug":"lymphoma","tag":"lymphoma","shared":3},{"slug":"adc","tag":"adc","shared":1},{"slug":"bispecific","tag":"bispecific","shared":1},{"slug":"trialist","tag":"trialist","shared":1}],"records":[{"id":"gilles-salles","kind":"person","name":"Gilles Salles","route":"/people/gilles-salles/","tldr":"Led PRIMA, which established rituximab maintenance in follicular lymphoma, and co-chaired POLARIX in DLBCL."},{"id":"herve-tilly","kind":"person","name":"Hervé Tilly","route":"/people/herve-tilly/","tldr":"Principal investigator of POLARIX, the trial that gave DLBCL its first improvement on R-CHOP in twenty years."},{"id":"catherine-thieblemont","kind":"person","name":"Catherine Thieblemont","route":"/people/catherine-thieblemont/","tldr":"Led EPCORE NHL-1, the trial that established the subcutaneous bispecific epcoritamab for relapsed large B-cell lymphoma."}]}